Introduction
============

Tiotropium bromide is an anticholinergic drug, categorized as a long-acting muscarinic antagonist (LAMA) or long-acting anticholinergic bronchodilator.[@b1-jaa-8-001] These drugs are used primarily in the management of chronic obstructive pulmonary disease (COPD), but interest in LAMA for the treatment of asthma has increased in recent years, particularly for patients whose asthma is poorly controlled with inhaled corticosteroids (ICS) and long-acting β~2~ agonists (LABA).[@b1-jaa-8-001]--[@b4-jaa-8-001] Despite clear guidelines and a range of available treatments, at least 50% of asthma patients continue to experience poor control of their current symptoms or future exacerbations, which significantly compromises the patient's quality of life and places considerable strain on health care systems.[@b1-jaa-8-001],[@b4-jaa-8-001] Thus, there is a need for additional therapeutic options.

The mechanisms by which LAMA have the potential to improve asthma control have recently been reviewed.[@b1-jaa-8-001] Briefly, LAMA may: induce bronchodilation, or inhibit cholinergically-mediated bronchoconstriction, and with regular use inhibit the airway smooth muscle hypertrophy and hyper-responsiveness characteristic of chronic asthma; reduce cholinergically-mediated mucus secretion and inhibit goblet cell hyperplasia and mucus gland hypertrophy; and moderate leukocyte responses in the lower airways as well as proinflammatory gene expression by airway smooth muscle and bronchial epithelium. In addition, LAMA such as tiotropium may act as steroid-sparing agents in patients with severe or poorly controlled asthma,[@b5-jaa-8-001],[@b6-jaa-8-001] which may alleviate some of the burden of corticosteroid use on health-related quality of life in these patients.[@b7-jaa-8-001]

A formulation of tiotropium delivered by soft mist inhaler has recently been approved in the UK[@b8-jaa-8-001] and in several other countries for add-on maintenance therapy in adults with asthma, specifically for patients who are currently treated with ICS and LABA yet experienced at least one severe exacerbation in the past year. Regulatory approval was based on the results of randomized controlled trials (RCTs) in patients with asthma which showed that addition of tiotropium to the existing controller regimen (ICS ± LABA) improved lung function,[@b2-jaa-8-001],[@b3-jaa-8-001],[@b9-jaa-8-001]--[@b13-jaa-8-001] and may improve symptom control[@b3-jaa-8-001],[@b11-jaa-8-001],[@b13-jaa-8-001] and lower the patient's exacerbation risk,[@b3-jaa-8-001] although it did not alter the use of rescue medications such as short-acting β~2~ agonists (SABAs).[@b2-jaa-8-001],[@b3-jaa-8-001],[@b10-jaa-8-001],[@b13-jaa-8-001]

However, these RCTs involved highly selected patient populations (for example, nonsmokers with no serious comorbidities) managed in tightly controlled settings, in most cases with relatively small patient numbers and short study periods.[@b2-jaa-8-001],[@b9-jaa-8-001]--[@b13-jaa-8-001] Their broader applicability requires the support of clinical studies that better represent real-life populations and situations.[@b14-jaa-8-001] Clinical studies on the effectiveness of LAMA as add-on therapy in real-life asthma care are still needed.

To that end, we examined the clinical effects of add-on therapy with tiotropium in a diverse group of over 2,000 asthma patients treated in UK primary care practice. Study patients were at least 18 years of age and had a physician-recorded diagnosis of asthma; patients with a recorded diagnosis of COPD were excluded, but no other clinically relevant exclusions were applied. By comparing exacerbation rates and other measures of asthma control in the year before and after the addition of tiotropium to the patient's asthma regimen, our goal was to determine whether the addition of LAMA improves asthma control in routine clinical practice.

Materials and methods
=====================

This historical, observational study of UK asthma patients used data obtained from the Optimum Patient Care Research Database (OPCRD; <http://www.optimumpatientcare.org>), which contains more than 5 million anonymized, longitudinal patient records from approximately 400 participating medical practices in the UK and is focused on patients with evidence of respiratory disease. The OPCRD has been approved by the Trent Multicentre Research Ethics Committee for use in clinical research, and the protocol for this study was approved by the Anonymised Data Ethics Protocols and Transparency Committee, which is the independent scientific advisory committee for the OPCRD.

Data were examined for the period 2001--2013. The medical record of each study patient was examined for the 12 months before (baseline) and 12 months after (outcome) the date of the patient's first prescription for tiotropium (index prescription date); hence, the index prescription dates spanned 2002--2012. Other LAMA drugs became available in the UK towards the end of the study period, but in the interest of investigating LAMA use in as many asthma patients as possible while using well-defined criteria, we limited the index prescription to tiotropium.

Two formulations of tiotropium bromide for inhalation were available in the UK during the study period: a dry-powder inhaler with a recommended dosage of 10 μg (the dose delivered from one 18 μg capsule) once a day[@b15-jaa-8-001] and a soft mist inhaler with a recommended dosage of 5 μg (two puffs of 2.5 μg) once a day.[@b8-jaa-8-001] Although equivalence data are not yet available for patients with asthma, these formulations and dosages have comparable bronchodilator efficacy in patients with COPD,[@b16-jaa-8-001],[@b17-jaa-8-001] so we chose to study the patients as a group, regardless of formulation/dosage.

The study patients had at least one prescription for tiotropium during the study window, had a recorded diagnosis of asthma, had no recorded diagnosis of COPD, were at least 18 years of age at the index prescription date, and had two continuous years of data (12 months each of baseline and outcome data). [Figure 1](#f1-jaa-8-001){ref-type="fig"} illustrates the patient selection process and study design.

Effectiveness measures
----------------------

The baseline year was used for patient characterization and the outcome year for evaluation of asthma-related effectiveness measures. A complete list of the baseline variables examined is provided in the Supplementary materials ([Table S1](#SD1-jaa-8-001){ref-type="supplementary-material"}), along with their definitions and methods of calculation.

The effectiveness measures compared before and after addition of tiotropium are described in [Table 1](#t1-jaa-8-001){ref-type="table"}. The two primary outcomes were exacerbations and acute respiratory events. We used the American Thoracic Society and European Respiratory Society definition of an exacerbation (asthma-related urgent hospital attendance/admission or acute course of systemic corticosteroids),[@b18-jaa-8-001] although we limited systemic corticosteroid use to an acute course of oral corticosteroids (OCS) accompanied by a lower respiratory consultation (physician visit coded as asthma, COPD, lower respiratory tract infection, or lung function/asthma monitoring, with further respiratory examination, thoracic radiographs, or referral). An acute respiratory event was defined as either an exacerbation or an antibiotic prescription accompanied by a lower respiratory consultation (which was taken to indicate that the physician treated the episode as a lower respiratory tract infection). Multiple qualifying events within a 2-week window were counted as a single exacerbation or acute respiratory event.

Secondary measures included the risk domain of asthma control (a proxy measure of asthma control as it pertains to exacerbation risk), specific components of the primary effectiveness measures (asthma-related acute OCS and antibiotic use), peak expiratory flow (PEF), forced expiratory volume in one second (FEV~1~), the ratio of FEV~1~ to forced vital capacity (FVC), and SABA usage. Asthma control in the risk domain was achieved if there were no episodes of asthma-related hospital, OCS, or antibiotic usage in the year of interest. As the measure of SABA usage, the prescribed SABA dosage was averaged over the year of interest, with all SABA dosages converted to salbutamol (albuterol) equivalents ([Table S1](#SD1-jaa-8-001){ref-type="supplementary-material"}).

Statistical analysis
--------------------

The statistical analysis was conducted using Statistical Package for the Social Sciences version 21 software (IBM Corporation, Armonk, NY, USA) and Microsoft Excel 2007 (Microsoft Corporation, Redmond, WA, USA). Statistical significance was defined as *P*\<0.05. Mean values are presented with their standard deviations and median values with their interquartile ranges (25th and 75th percentiles). Where data were not normally distributed, median (interquartile range) values are reported.

Summary statistics were generated for all baseline and outcome variables. The number of exacerbations in the year before and after initiating tiotropium was then compared using the Wilcoxon signed-rank test for exacerbation counts measured on the interval scale and the marginal homogeneity test for categorized exacerbation data. These tests were also used to compare baseline and outcome years for acute respiratory events, acute OCS courses, antibiotic prescriptions, and SABA usage. The paired *t*-test was used to compare baseline and outcome years for PEF and FEV~1~, and the marginal homogeneity test was used for comparison of categorized FEV~1~/FVC ratios. The proportion of patients achieving asthma control in the risk domain was compared between baseline and outcome years using the McNemar test.

Sensitivity analysis
--------------------

Although the selection process deliberately excluded asthma patients who also had a recorded diagnosis of COPD, some patients with undiagnosed or unrecorded COPD may have been included, given the average age of the study patients and the prevalence of current or former smokers. For this reason, the primary analyses (exacerbations and acute respiratory events) were repeated for a subset of patients who were unlikely to have COPD based on the following criteria: ≤40 years of age, \>40 years of age but never smoked, and \>40 years of age with no evidence of airway obstruction (baseline FEV~1~/FVC ratio ≥0.7).

Results
=======

A total of 2,042 patients met the study criteria. The dry powder formulation of tiotropium was prescribed in 1,898 patients (93%) and the soft mist inhaler in 144 patients (7%). Key baseline patient characteristics are summarized in [Tables 2](#t2-jaa-8-001){ref-type="table"} and [3](#t3-jaa-8-001){ref-type="table"}; complete baseline data are provided in the Supplementary materials ([Tables S2](#SD2-jaa-8-001){ref-type="supplementary-material"}--[S6](#SD6-jaa-8-001){ref-type="supplementary-material"}). The mean age was 63 years; 59% of patients were female; the mean body mass index was 29 kg/m^2^; and of those whose smoking history was known, 54% were either current (17%) or former (37%) smokers. In the patients with baseline lung function data, the mean PEF was 69% of predicted normal, the mean FEV~1~ was 59% of predicted normal, and the mean FEV~1~/FVC ratio was 0.61; only 40% of the patients with FEV~1~ and FVC data had a ratio ≥0.7.

At baseline, most patients were being treated according to British Thoracic Society guidelines[@b19-jaa-8-001] step 3 (21.5%) or step 4 (49.5%; [Table S5](#SD5-jaa-8-001){ref-type="supplementary-material"}). An ICS was prescribed in 83% of patients and a LABA in 68% of patients; 67% were prescribed both ([Table S5](#SD5-jaa-8-001){ref-type="supplementary-material"}). Median adherence to ICS therapy ([Table S1](#SD1-jaa-8-001){ref-type="supplementary-material"}) was 100%, with 51% of patients having ≥100% adherence ([Table S5](#SD5-jaa-8-001){ref-type="supplementary-material"}). The median controller-reliever ratio ([Table S1](#SD1-jaa-8-001){ref-type="supplementary-material"}) was 0.5, indicating approximately equal use of controller (ICS or leukotriene receptor antagonist) and reliever (SABA) medications, although 59% of patients had a ratio ≥0.5 ([Table S5](#SD5-jaa-8-001){ref-type="supplementary-material"}), indicating relatively more controller than reliever use. During their baseline year, 37% of patients had at least one exacerbation, 58% had at least one acute respiratory event, and 41% achieved asthma control in the risk domain ([Table 3](#t3-jaa-8-001){ref-type="table"}).

Outcomes
--------

Comparisons between baseline and outcome years for the various effectiveness measures are summarized in [Table 3](#t3-jaa-8-001){ref-type="table"} and illustrated in [Figures 2](#f2-jaa-8-001){ref-type="fig"}--[4](#f4-jaa-8-001){ref-type="fig"}, with further details provided in [Table S6](#SD6-jaa-8-001){ref-type="supplementary-material"}. Addition of tiotropium was associated with significantly fewer exacerbations ([Figure 2](#f2-jaa-8-001){ref-type="fig"}) and acute respiratory events ([Figure 3](#f3-jaa-8-001){ref-type="fig"}); 27% of patients had at least one exacerbation, 47% had at least one acute respiratory event, and 52% achieved asthma control in the risk domain during the outcome year ([Table 3](#t3-jaa-8-001){ref-type="table"}). In addition, tiotropium use was associated with significantly less asthma-related acute OCS and antibiotic use ([Tables 3](#t3-jaa-8-001){ref-type="table"} and S6). Comparing baseline and outcome years, SABA usage significantly increased ([Figure 4](#f4-jaa-8-001){ref-type="fig"}), but there were no significant changes in PEF, FEV~1~, or FEV~1~/FVC ratio in the patients with paired baseline and outcome data for those variables ([Table 3](#t3-jaa-8-001){ref-type="table"}).

Sensitivity analysis
--------------------

The sensitivity analysis was conducted on 928 patients (45% of the full study group) with the least likelihood of also having COPD. Baseline characteristics are summarized in [Table 4](#t4-jaa-8-001){ref-type="table"}, distributed by age group (≤40 and \>40 years). Compared with the full study group, proportionately more patients in this subset were female (65%) and nonsmokers (76%), and fewer were current (9%) or former (15%) smokers. The mean FEV~1~/FVC ratio was 0.8. The rates of exacerbations and acute respiratory events during the baseline year were comparable with those of the full study group, and the addition of tiotropium was associated with a similar decrease in exacerbations and acute respiratory events during the outcome year ([Tables 5](#t5-jaa-8-001){ref-type="table"} and S7).

Discussion
==========

Our study showed that primary care physicians in the UK have been prescribing LAMA for the treatment of asthma since 2002, even though there were no UK license or guideline recommendations for LAMA use in patients with asthma until September 2014.[@b15-jaa-8-001] It was not possible with our study design to determine why a LAMA was prescribed in these patients. However, 93% of the patients were over 40 years of age and 62% were over 60 years of age, more than 50% of whom were current or former smokers ([Table S3](#SD3-jaa-8-001){ref-type="supplementary-material"}). Most had significant comorbidities ([Table S2](#SD2-jaa-8-001){ref-type="supplementary-material"}), and many had impairments of lung function and asthma control in the risk domain despite treatment with moderate to high doses of ICS ± LABA, ≥100% adherence to their ICS prescriptions, and controller-reliever ratios indicative of equal or greater use of controller medications throughout the year. Thus, it appears that physicians were prescribing LAMA predominantly as add-on therapy in older patients with poorly controlled asthma despite good treatment compliance, particularly in those who were current or former smokers.

In this population, addition of tiotropium was associated with a significant decrease in the incidence of exacerbations and other acute respiratory events (specifically, antibiotic prescriptions for lower respiratory tract infection), and a significant increase in the rate of asthma control in the risk domain over the following year. Whereas most of the aforementioned clinical trials emphasized current symptom control, our study was focused primarily on the effects of LAMA on the patient's exacerbation risk, as exacerbations have such a negative impact on the patient's quality of life and on health care resources.[@b20-jaa-8-001] The RCT by Kerstjens et al[@b3-jaa-8-001] showed a significant reduction in exacerbation risk with the addition of tiotropium; however, their patient population was younger than our study group by about 10 years (mean age, 53 years), 76% of their patients had never smoked, the remainder had a smoking history of \<10 pack-years, and none of their patients had serious coexisting illnesses. Thus, it may be particularly noteworthy that in our study LAMA therapy was associated with a decrease in exacerbations even under less-than-ideal conditions. Also of note, LAMA use in our study was associated with a significant reduction in acute OCS use, which may be expected to reduce the multifaceted treatment burden documented for corticosteroid use in patients with severe or poorly controlled asthma.[@b7-jaa-8-001]

Given our study design, it may be argued that regression toward the mean could have contributed to the differences found between baseline and outcome years. This issue may have been obviated by using a matched control group not prescribed tiotropium, although such an approach would almost certainly have led to the loss of unmatched but otherwise qualified patients prescribed tiotropium and thus to a smaller number and perhaps less diverse group of patients for study. As it was, our study design involved data collected over 2 consecutive years within a continuum of ongoing therapy in long-term asthma patients that, for the group, spanned over a decade (2001--2013); and with the exception of the lung function indices, the baseline and outcome values each represented a full year of data, not repeated measures of single, isolated points in time. Thus, if regression toward the mean was a factor in our study results, its influence was likely small. Furthermore, our findings are supported by those of Kerstjens et al,[@b3-jaa-8-001] who showed in two replicate, randomized, double-blind, placebo-controlled, parallel-group clinical trials involving 48-week study periods and 912 patients in 15 countries that addition of tiotropium significantly increased the time to first exacerbation and decreased the exacerbation risk in patients whose asthma was poorly controlled despite maintenance treatment with ICS and LABA.

A legitimate concern, given our study design and patient demographics, is that the group may have included some asthma patients who also had undiagnosed or unrecorded COPD. The sensitivity analysis, limited to the patients least likely to have COPD, was conducted to address this issue. In this subset, addition of tiotropium was associated with decreases in the incidence of exacerbations and other acute respiratory events (specifically, antibiotic prescriptions for lower respiratory tract infection) similar to that found in the full study group. Thus, it is reasonable to conclude that LAMA therapy may be associated with a decrease in asthma exacerbations whether or not the patient may also have COPD.

A further criticism is that no separate control or comparator group was included, and treatment was not randomized. Our study purpose was to retrospectively examine the outcomes of clinical decisions made by primary care physicians with regard to the use of LAMA therapy in real-life patients with asthma. There was therefore no opportunity for us to randomize treatment, and as discussed above, our decision not to include a matched control group was made deliberately and with the goal of generating as large and diverse a treatment group as possible. Thus, our study patients served as their own controls, the comparisons in asthma-related effectiveness measures being made between the year before and the year after initiating LAMA therapy. Despite this and other limitations imposed by our study design, our findings are generally consistent with those of the RCTs that included placebo[@b2-jaa-8-001],[@b3-jaa-8-001],[@b9-jaa-8-001]--[@b12-jaa-8-001] or comparator drug groups.[@b10-jaa-8-001],[@b13-jaa-8-001]

Yet another potential shortcoming of our study design is that not all study patients had lung function data, and in those who did, no constraints could be placed on the timing of the lung function tests with regard to time of day (morning or evening) or bronchodilator administration (before or after bronchodilation), when the tests were performed in the outcome year relative to initiation of tiotropium therapy, nor on quality control of the measurements. In comparison, licensing studies require centralized spirometry over-reading to ensure high quality spirometry. In order to maximize patient numbers, we elected not to limit the study group to only those patients with paired lung function data. Physicians evidently were prescribing LAMA for patients with asthma even in the absence of lung function tests, so our full study group reflects recent clinical practices and outcomes.

The inability to dictate the timing and performance of the lung function tests in our study likely contributed to the large variations found in lung function values. Along with patient age and inclusion of smokers, that may explain the lack of significant changes in lung function with the addition of tiotropium, when improvements in lung function were a consistent RCT finding.[@b2-jaa-8-001],[@b3-jaa-8-001],[@b9-jaa-8-001]--[@b13-jaa-8-001] It is worth noting, however, that the RCT improvements in lung function with the addition of tiotropium, while statistically significant, often were small, and they were not consistently accompanied by improvements in asthma control or quality of life.[@b2-jaa-8-001],[@b3-jaa-8-001],[@b9-jaa-8-001],[@b12-jaa-8-001],[@b13-jaa-8-001]

Between baseline and outcome years, the change in SABA usage in our study group, while statistically significant, was small and may be considered of little clinical relevance. This finding is consistent with RCT results for tiotropium use in patients with asthma,[@b2-jaa-8-001],[@b3-jaa-8-001],[@b10-jaa-8-001],[@b13-jaa-8-001] but it is somewhat at odds with the classification of tiotropium as a long-acting bronchodilator that is administered once daily,[@b8-jaa-8-001],[@b15-jaa-8-001] and with the proposed mechanisms by which LAMA may improve asthma control.[@b1-jaa-8-001] A longer investigation period may be required to determine whether or not LAMA perform in practice as these mechanisms propose. In the meantime, it is useful to know that addition of tiotropium to the current treatment regimen may reduce the asthma patient's exacerbation risk within the first year of treatment.

Conclusion
==========

In this real-life population of adults with asthma treated in routine clinical practice, addition of a LAMA to the current treatment regimen was associated with a decrease in exacerbations and other acute respiratory events (specifically, antibiotic prescriptions for lower respiratory tract infections) in the following year.

Supplementary materials
=======================

###### 

Baseline variables examined

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                                                                                                             Description
  ------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables examined at, or closest to, the index prescription date:[a](#tfn21-jaa-8-001){ref-type="table-fn"}                         

   Age                                                                                                                                 In years; also categorized as 18--40, 41--60, or \>60 years

   Gender                                                                                                                              Male or female

   Body mass index                                                                                                                     In kg/m^2^; categorized as underweight (\<18.5), normal (18.5--24.9), overweight (25--29.9), or obese (≥30)

   Smoking status                                                                                                                      Nonsmoker, current smoker, ex-smoker, or unknown

   PEF, % predicted                                                                                                                    Predicted normal PEF (L/sec) was calculated as follows: for men, (5.317× height \[m\]) − (0.062× age \[years\]) +3.884; for women, (4.087× height \[m\]) − (0.05× age \[years\]) +2.945; the patient's PEF reading was compared with the predicted value and expressed as a percentage of predicted normal

   FEV~1~, % predicted                                                                                                                 Predicted normal FEV~1~ (L) was calculated as follows: for men, (4.3× height \[m\]) − (0.029 × age \[years\]) −2.49; for women, (3.95× height \[m\]) − (0.025× age \[years\]) −2.6; for both, 25 years was used for age in patients 18--25 years; the patient's\
                                                                                                                                       FEV~1~ reading was compared with the predicted value and expressed as a percentage of predicted normal

   FVC                                                                                                                                 Used to calculate FEV~1~/FVC ratio; also categorized as \<0.5, 0.5--0.69, or ≥0.7

  Variables examined regardless of when they occurred relative to index prescription date:[a](#tfn21-jaa-8-001){ref-type="table-fn"}   

   First asthma diagnosis                                                                                                              Date when asthma first diagnosed (if known)

   Comorbidities                                                                                                                       Including rhinitis (or prescription for rhinitis nasal spray), gastroesophageal reflux disease, and cardiac disease (or prescription for cardiac drugs)

   Charlson comorbidity index score[b](#tfn22-jaa-8-001){ref-type="table-fn"}                                                          Categorized as 0, 1--4, or 5+

  Variables examined in the year before the index prescription date:[a](#tfn21-jaa-8-001){ref-type="table-fn"}                         

   Respiratory treatments                                                                                                              All asthma, allergy, and other respiratory treatments

   ICS usage                                                                                                                           Where ICS prescribed, number of inhalers, dosage, and average daily dosage (averaged over the year); all ICS dosages are in FP equivalents: large-particle BDP and budesonide dosages were divided by 2 to yield the FP-equivalent dosage;extra-fine particle BDP and ciclesonide dosages were considered directly equivalent to FP dosages for this study

   General practice consultations                                                                                                      Number of general practice consultations, total and asthma-related

   Acute OCS courses                                                                                                                   Number of acute OCS courses accompanied by lower respiratory consultation;[c](#tfn23-jaa-8-001){ref-type="table-fn"} total and categorized as 0, 1, 2, or 3+

   BTS step                                                                                                                            Treatment step (1--5), as described by BTS guidelines;[d](#tfn24-jaa-8-001){ref-type="table-fn"} step 0 was added to denote patients prescribed no asthma treatment

   Hospitalization                                                                                                                     Number of asthma-related A&E attendances, inpatient admissions, or outpatient visits

   SABA usage                                                                                                                          Prescribed SABA dosage, averaged over the year: (\[number of inhalers × doses per inhaler\] ÷365) × strength (μg); all SABA dosages are in salbutamol (albuterol) equivalents: terbutaline dosages were divided by 2.5 to yield the salbutamol-equivalent dosage; average daily dosage and categorized as 0, 1--200, 201--400, or \>400 μg/day

   Risk domain of asthma control                                                                                                       A composite proxy measure of exacerbation risk (see text); controlled or uncontrolled

   Antibiotic prescriptions                                                                                                            Number of antibiotic prescriptions accompanied by lower respiratory consultation;[c](#tfn23-jaa-8-001){ref-type="table-fn"} total and categorized as 0, 1, 2, or 3+

   Other medications                                                                                                                   Prescription for β-blockers, NSAIDs, paracetamol (acetaminophen), tricyclic antidepressants, and statins

   Exacerbations                                                                                                                       Number of asthma exacerbations (see text); total and categorized as 0, 1, 2, or 3+

   Acute respiratory events                                                                                                            Number of acute events (see text); total and categorized as 0, 1, 2, or 3+

   Adherence to ICS therapy                                                                                                            Adherence (%) = (total pack days ÷365) ×100; where total pack days = sum (number of days/pack), and days/pack = actuations/pack ÷ actuations/day

   Controller-reliever ratio                                                                                                           Calculated as units of controllers ÷ (units of controllers + units of relievers); controllers included ICS and LTRA, one unit = one inhaler for ICS or one prescription for LTRA; relievers were limited to SABA, one unit = one inhaler; LABA were excluded from this analysis, as ICS-LABA combination inhalers would have skewed the results
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Date of the patient's first tiotropium prescription

Aylin P, Bottle A, Jen MH, et al. HSMR mortality indicators. London, UK: Doctor Foster Research; 2010. Available from: <http://www.nhs.uk/scorecard/Documents/HSMR%20methodology%2009%20November.pdf>. Accessed on March 15, 2013

any lower respiratory consultation (asthma, COPD, or LRTI code, or lung function/asthma monitoring) with additional respiratory examinations, chest X-rays, and referrals

British Guideline on the Management of Asthma. London, UK: British Thoracic Society; 2014. Available from: <https://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guideline-2014/>.

**Abbreviations:** A&E, Accident and Emergency Department; BDP, beclomethasone dipropionate; BTS, British Thoracic Society; COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in one second; FP, fluticasone propionate; FVC, forced vital capacity; ICS, inhaled corticosteroid; LABA, long-acting β~2~ agonist; LTRA, leukotriene receptor antagonist; LRTI, lower respiratory tract infection; NSAIDs, nonsteroidal anti-inflammatory drugs; OCS, oral corticosteroid; PEF, peak expiratory flow; SABA, short-acting β~2~ agonist.

###### 

Baseline patient characteristics: demographic and clinical variables

  ------------------------------------------------------------ ---------------
  Age (years)                                                  
   Mean (SD)                                                   63.4 (14.2)
   18--40, n (%)                                               136 (6.7%)
   41--60, n (%)                                               637 (31.2%)
   \>60, n (%)                                                 1,269 (62.1%)
  Gender                                                       
   Female, n (%)                                               1,208 (59.2%)
  BMI (kg/m^2^); n (%)                                         1,959 (95.6%)
   Mean (SD)                                                   29.2 (6.7)
   Underweight (\<18.5), n (%)                                 42 (2.1%)
   Normal (18.5--24.9), n (%)                                  488 (24.9%)
   Overweight (25--29.9), n (%)                                664 (33.9%)
   Obese (≥30), n (%)                                          765 (39.1%)
  Smoking status, n (%)                                        
   Nonsmoker                                                   849 (41.6%)
   Current smoker                                              322 (15.8%)
   Ex-smoker                                                   682 (33.4%)
   Unknown                                                     189 (9.2%)
  PEF (% predicted), n (%)                                     1,358 (66.5%)
   Mean (SD)                                                   69.3 (21.8)
  FEV~1~ (% predicted), n (%)                                  848 (41.5%)
   Mean (SD)                                                   59.0 (29.0)
  FEV~1~/FVC ratio, n (%)                                      780 (38.2%)
   Mean (SD)                                                   0.61 (0.24)
   \<0.5, n (%)                                                225 (28.8%)
   0.5--0.69, n (%)                                            244 (31.3%)
   ≥0.7, n (%)                                                 311 (39.9%)
  CCI score, n (%)                                             
   0                                                           746 (36.5%)
   1--4                                                        854 (41.8%)
   5+                                                          442 (21.6%)
  Comorbidities, n (%)                                         
   Rhinitis[a](#tfn27-jaa-8-001){ref-type="table-fn"}          730 (35.7%)
   GERD                                                        301 (14.7%)
   Cardiac disease[b](#tfn28-jaa-8-001){ref-type="table-fn"}   1,286 (63.0%)
   Ischemic heart disease                                      308 (15.1%)
  Comedications prescribed, n (%)                              
   β blocker                                                   127 (6.2%)
   NSAID                                                       820 (40.2%)
   Paracetamol                                                 906 (44.4%)
   Tricyclic antidepressant                                    221 (10.8%)
   Statin                                                      618 (30.3%)
  ------------------------------------------------------------ ---------------

**Notes:** n=2,042, unless otherwise noted;

diagnosis at any time or nasal spray prescribed during baseline or outcome year

diagnosis or cardiac drugs prescribed at any time.

**Abbreviations:** BMI, body mass index; CCI, Charlson Comorbidity Index; FEV~1~, forced expiratory volume in one second, expressed as percentage of predicted normal; FVC, forced vital capacity; GERD, gastroesophageal reflux disease; NSAID, nonsteroidal anti-inflammatory drug; PEF, peak expiratory flow, expressed as percentage of predicted normal; SD, standard deviation.

###### 

Baseline smoking status by age group

  Age group             Smoking status                               
  --------------------- ---------------- ------------- ------------- -------------
  18--40 years, n (%)   58 (6.8%)        39 (12.1%)    26 (3.8%)     13 (6.9%)
  41--60 years, n (%)   228 (26.9%)      168 (52.2%)   186 (27.3%)   55 (29.1%)
  \>60 years, n (%)     563 (66.3%)      115 (35.7%)   470 (68.9%)   121 (64.0%)
  Total, n (%)          849 (100%)       322 (100%)    682 (100%)    189 (100%)

###### 

Distribution of baseline FEV~1~/FVC ratio in patients over 60 years of age, by smoking status

  FEV~1~/FVC ratio   All           Current smokers   Ex-smokers
  ------------------ ------------- ----------------- ------------
  \<0.5, n (%)       156 (29.1%)   16 (32.7%)        74 (33.9%)
  0.5--0.69, n (%)   176 (32.8%)   19 (38.8%)        64 (29.4%)
  ≥0.7, n (%)        204 (38.1%)   14 (28.6%)        80 (36.7%)
  Total, n (%)       536 (100%)    49 (100%)         218 (100%)

**Abbreviations:** FEV~1~, forced expiratory volume in one second, expressed as percentage of predicted normal; FVC, forced vital capacity.

###### 

Baseline patient characteristics: asthma treatment and control

  ------------------------------------------------------------------------------------------------------------------------- ------------------
  SABA inhalers, n                                                                                                          
   Median (IQR)                                                                                                             5 (2, 10)
  Primary care consultations, n                                                                                             
   Median (IQR)                                                                                                             14 (9, 22)
  Asthma consultations,[a](#tfn32-jaa-8-001){ref-type="table-fn"} n                                                         
   Median (IQR)                                                                                                             1 (0, 2)
   0, n (%)                                                                                                                 664 (32.5%)
   1, n (%)                                                                                                                 593 (29.0%)
   2, n (%)                                                                                                                 347 (17.0%)
   3+, n (%)                                                                                                                438 (21.4%)
  Specific asthma medications, n (%)                                                                                        
   None                                                                                                                     117 (5.7%)
   SABA only                                                                                                                149 (7.3%)
   SAAC only                                                                                                                11 (0.5%)
   SABA + SAAC                                                                                                              35 (1.7%)
   LABA ± SABA/SAAC                                                                                                         21 (1.0%)
   ICS ± SABA/SAAC                                                                                                          301 (14.7%)
   ICS + LABA ± SABA/SAAC                                                                                                   1,055 (51.7%)
   LTRA ± SABA/SAAC                                                                                                         16 (0.8%)
   ICS + LTRA ± SABA/SAAC                                                                                                   27 (1.3%)
   ICS + LABA + LTRA ± SABA/SAAC                                                                                            307 (15.0%)
   LABA + LTRA + theophylline ± SABA/SAAC                                                                                   2 (0.1%)
   Theophylline                                                                                                             1 (\<0.1%)
  ICS inhalers, n                                                                                                           
   Median (IQR)                                                                                                             6 (2, 10)
  Baseline ICS dosage (μg/day)[b](#tfn33-jaa-8-001){ref-type="table-fn"},[c](#tfn34-jaa-8-001){ref-type="table-fn"}         
   Median (IQR)                                                                                                             247 (66, 493)
   0, n (%)                                                                                                                 352 (17.2%)
   1--100, n (%)                                                                                                            296 (14.5%)
   101--200, n (%)                                                                                                          311 (15.2%)
   201--400, n (%)                                                                                                          385 (18.9%)
   401--800, n (%)                                                                                                          436 (21.4%)
   \>800, n (%)                                                                                                             262 (12.8%)
  ICS dosage pre-IPD (μg/day),[c](#tfn34-jaa-8-001){ref-type="table-fn"},[d](#tfn35-jaa-8-001){ref-type="table-fn"} n (%)   1,690 (82.8%)
   Median (IQR)                                                                                                             500 (200, 1,000)
  ICS dosage at IPD (μg/day),[c](#tfn34-jaa-8-001){ref-type="table-fn"} n (%)                                               537 (26.3%)
   Median (IQR)                                                                                                             500 (400, 1,000)
  Adherence to ICS (%), n (%)                                                                                               1,690 (82.8%)
   Median (IQR)                                                                                                             100 (73, 134)
   \<50%, n (%)                                                                                                             201 (11.9%)
   50%--69.9%, n (%)                                                                                                        185 (10.9%)
   70%--99.9%, n (%)                                                                                                        451 (26.7%)
   ≥100%, n (%)                                                                                                             853 (50.5%)
  Controller-reliever ratio, n (%)                                                                                          1,909 (93.5%)
   Median (IQR)                                                                                                             0.5 (0.3, 0.7)
   \<0.5, n (%)                                                                                                             787 (41.2%)
   ≥0.5, n (%)                                                                                                              1,122 (58.8%)
  LABA prescribed, n (%)                                                                                                    1,385 (67.8%)
  Spacer device used, n (%)                                                                                                 279 (13.7%)
  BTS step, n (%)                                                                                                           
   0                                                                                                                        118 (5.8%)
   1                                                                                                                        212 (10.4%)
   2                                                                                                                        252 (12.3%)
   3                                                                                                                        439 (21.5%)
   4                                                                                                                        1,011 (49.5%)
   5                                                                                                                        10 (0.5%)
  Hospitalization, ≥1[e](#tfn36-jaa-8-001){ref-type="table-fn"}; n (%)                                                      
   A&E                                                                                                                      25 (1.2%)
   Inpatient                                                                                                                22 (1.1%)
   Outpatient                                                                                                               22 (1.1%)
  ------------------------------------------------------------------------------------------------------------------------- ------------------

**Notes:** n=2,042, unless otherwise noted;

nonspecialist primary care consultations where asthma was recorded

prescribed ICS dosage, averaged over the baseline year

in fluticasone-propionate equivalents

dosage prescribed at most recent consultation before IPD

at least one asthma-related hospital visit during baseline year (categorized).

**Abbreviations:** A&E, Accident and Emergency Department; BTS, British Thoracic Society; ICS, inhaled corticosteroid; IPD, index prescription date (date of first tiotropium script); IQR, interquartile range; LABA, long-acting β~2~ agonist; LTRA, leukotriene receptor antagonist; SAAC, short-acting anticholinergic; SABA, short-acting β~2~ agonist.

###### 

Comparison of effectiveness measures before (baseline) and after (outcome) addition of tiotropium

  Variable                                                        Baseline         Outcome          *P*-value
  --------------------------------------------------------------- ---------------- ---------------- ---------------------------------------------------
  Exacerbations                                                                                     \<0.001[a](#tfn39-jaa-8-001){ref-type="table-fn"}
   Median (IQR)                                                   0 (0, 1)         0 (0, 1)         
   0, n (%)                                                       1,290 (63.2%)    1,499 (73.4%)    \<0.001[b](#tfn40-jaa-8-001){ref-type="table-fn"}
   1, n (%)                                                       415 (20.3%)      330 (16.2%)      
   2, n (%)                                                       180 (8.8%)       116 (5.7%)       
   3+, n (%)                                                      157 (7.7%)       97 (4.8%)        
  Acute respiratory events                                                                          \<0.001[a](#tfn39-jaa-8-001){ref-type="table-fn"}
   Median (IQR)                                                   1 (0, 2)         0 (0, 1)         
   0, n (%)                                                       851 (41.7%)      1,077 (52.7%)    \<0.001[b](#tfn40-jaa-8-001){ref-type="table-fn"}
   1, n (%)                                                       498 (24.4%)      506 (24.8%)      
   2, n (%)                                                       328 (16.1%)      218 (10.7%)      
   3+, n (%)                                                      365 (17.9%)      241 (11.8%)      
  Risk domain of asthma control                                                                     
   Controlled, n (%)                                              846 (41.4%)      1,071 (52.4%)    \<0.001[c](#tfn41-jaa-8-001){ref-type="table-fn"}
  Acute OCS courses                                                                                 \<0.001[a](#tfn39-jaa-8-001){ref-type="table-fn"}
   Median (IQR)                                                   0 (0, 1)         0 (0, 1)         
   0, n (%)                                                       1,310 (64.2%)    1,521 (74.5%)    \<0.001[b](#tfn40-jaa-8-001){ref-type="table-fn"}
   1, n (%)                                                       402 (19.7%)      316 (15.5%)      
   2, n (%)                                                       175 (8.6%)       115 (5.6%)       
   3+, n (%)                                                      155 (7.6%)       90 (4.4%)        
  Antibiotic prescriptions                                                                          \<0.001[a](#tfn39-jaa-8-001){ref-type="table-fn"}
   Median (IQR)                                                   1 (0, 2)         0 (0, 1)         
   0, n (%)                                                       999 (48.9%)      1,200 (58.8%)    \<0.001[b](#tfn40-jaa-8-001){ref-type="table-fn"}
   1, n (%)                                                       469 (23.0%)      440 (21.5%)      
   2, n (%)                                                       268 (13.1%)      196 (9.6%)       
   3+, n (%)                                                      306 (15.0%)      206 (10.1%)      
  PEF (% predicted), n (%)                                        926 (45.3%)      926 (45.3%)      
   Mean (SD)                                                      70.0 (21.5)      69.5 (21.7)      0.371[d](#tfn42-jaa-8-001){ref-type="table-fn"}
  FEV~1~ (% predicted), n (%)                                     398 (19.5%)      398 (19.5%)      
   Mean (SD)                                                      58.0 (29.5)      57.9 (30.5)      0.935[d](#tfn42-jaa-8-001){ref-type="table-fn"}
  FEV~1~/FVC ratio, n (%)                                         353 (17.3%)      353 (17.3%)      
   \<0.5                                                          91 (25.8%)       116 (32.9%)      0.382[b](#tfn40-jaa-8-001){ref-type="table-fn"}
   0.5--0.69                                                      122 (34.6%)      86 (24.4%)       
   ≥0.7                                                           140 (39.7%)      151 (42.8%)      
  SABA usage (μg/day)[e](#tfn43-jaa-8-001){ref-type="table-fn"}                                     0.010[a](#tfn39-jaa-8-001){ref-type="table-fn"}
   Median (IQR)                                                   274 (110, 548)   329 (110, 603)   
   0, n (%)                                                       327 (16.0%)      317 (15.5%)      0.006[b](#tfn40-jaa-8-001){ref-type="table-fn"}
   1--200, n (%)                                                  493 (24.1%)      450 (22.0%)      
   201--400, n (%)                                                451 (22.1%)      451 (22.1%)      
   \>400, n (%)                                                   771 (37.8%)      824 (40.4%)      

**Notes:** n=2,042, unless otherwise noted;

Wilcoxon signed-rank test

marginal homogeneity test

McNemar test

paired *t*-test

in salbutamol (albuterol) equivalents.

**Abbreviations:** FEV~1~, forced expiratory volume in one second, expressed as percentage of predicted normal; FVC, forced vital capacity; IQR, interquartile range; OCS, oral corticosteroid; PEF, peak expiratory flow, expressed as percentage of predicted normal; SABA, short-acting β~2~ agonist; SD, standard deviation.

###### 

Sensitivity analysis: comparison of primary measures before (baseline) and after (outcome) addition of tiotropium

  Variable                   Baseline      Outcome       *P*-value
  -------------------------- ------------- ------------- ---------------------------------------------------
  Exacerbations                                          \<0.001[a](#tfn46-jaa-8-001){ref-type="table-fn"}
   Median (IQR)              0 (0, 1)      0 (0, 1)      
   0, n (%)                  565 (60.9%)   654 (70.5%)   \<0.001[b](#tfn47-jaa-8-001){ref-type="table-fn"}
   1, n (%)                  198 (21.3%)   167 (18.0%)   
   2, n (%)                  93 (10.0%)    62 (6.7%)     
   3+, n (%)                 72 (7.8%)     45 (4.8%)     
  Acute respiratory events                               \<0.001[a](#tfn46-jaa-8-001){ref-type="table-fn"}
   Median (IQR)              1 (0, 2)      0 (0, 1)      
   0, n (%)                  361 (38.9%)   476 (51.3%)   \<0.001[b](#tfn47-jaa-8-001){ref-type="table-fn"}
   1, n (%)                  231 (24.9%)   228 (24.6%)   
   2, n (%)                  149 (16.1%)   108 (11.6%)   
   3+, n (%)                 187 (20.2%)   116 (12.5%)   

**Notes:** n=928;

Wilcoxon signed-rank test

marginal homogeneity test.

**Abbreviation:** IQR, interquartile range.
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**Abbreviation:** COPD, chronic obstructive pulmonary disease.](jaa-8-001Fig1){#f1-jaa-8-001}
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![SABA usage before (baseline) and after (outcome) addition of tiotropium. Dosages are in salbutamol (albuterol) equivalents; *P*=0.006 (marginal homogeneity test) comparing baseline and outcome years.\
**Abbreviation:** SABA, short-acting β~2~ agonist.](jaa-8-001Fig4){#f4-jaa-8-001}

###### 

Effectiveness measures compared before and after addition of tiotropium

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                                         Definition
  ---------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------
  Primary                                                          

   Exacerbations                                                   Number of exacerbations, defined as occurrence of one of the following:\
                                                                   1. Asthma-related urgent hospital visit (A&E or inpatient)\
                                                                   2. Acute OCS course with evidence of LRT consultation[a](#tfn1-jaa-8-001){ref-type="table-fn"}

   Acute respiratory events                                        Number of events, defined as occurrence of one of the following:\
                                                                   1. Exacerbation\
                                                                   2. Antibiotic prescription with evidence of LRT consultation[a](#tfn1-jaa-8-001){ref-type="table-fn"}

  Secondary                                                        

   Risk domain of asthma control                                   Controlled/uncontrolled\
                                                                   Controlled if absence of all the following:\
                                                                   1. Asthma-related hospital visit (A&E, inpatient, or outpatient)\
                                                                   2. Acute OCS course with evidence of LRT consultation[a](#tfn1-jaa-8-001){ref-type="table-fn"}\
                                                                   3. Antibiotic prescription with evidence of LRT consultation[a](#tfn1-jaa-8-001){ref-type="table-fn"}\
                                                                   Uncontrolled if any such events occurred in the year of interest

   Acute OCS courses                                               Number of acute OCS courses with evidence of LRT consultation[a](#tfn1-jaa-8-001){ref-type="table-fn"}

   Antibiotic prescriptions                                        Number of antibiotic prescriptions with evidence of LRT consultation[a](#tfn1-jaa-8-001){ref-type="table-fn"}

   PEF (% predicted)[b](#tfn2-jaa-8-001){ref-type="table-fn"}      Peak expiratory flow (PEF), expressed as percentage of predicted normal

   FEV~1~ (% predicted)[b](#tfn2-jaa-8-001){ref-type="table-fn"}   Forced expiratory volume in one second (FEV~1~), expressed as percentage of predicted normal

   FEV~1~/FVC ratio[b](#tfn2-jaa-8-001){ref-type="table-fn"}       Ratio of FEV~1~ to forced vital capacity (FVC)

   SABA usage                                                      Prescribed SABA dosage, averaged over the year of interest, in salbutamol (albuterol) equivalents
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Any lower respiratory consultation (asthma, COPD, or LRT infection code, or lung function/asthma monitoring) with additional respiratory examinations, including chest X-rays and referrals

when paired baseline and outcome data were available.

**Abbreviations:** A&E, Accident and Emergency Department; COPD, chronic obstructive pulmonary disease; LRT, lower respiratory tract; OCS, oral corticosteroid; SABA, short-acting β~2~ agonist.

###### 

Key descriptive characteristics at baseline

  --------------------------------------------------------------------- ------------------------------------------------------
  Age (years)                                                           
   Mean (SD)                                                            63.4 (14.2)
   \>40 years, n (%)                                                    1,906 (93.3%)
  Gender, female; n (%)                                                 1,208 (59.2%)
  BMI (kg/m^2^); n (%)                                                  1,959 (95.6%)
   Mean (SD)                                                            29.2 (6.7)
   Overweight, n (%)                                                    664 (33.9%)[a](#tfn5-jaa-8-001){ref-type="table-fn"}
   Obese, n (%)                                                         765 (39.1%)[a](#tfn5-jaa-8-001){ref-type="table-fn"}
  Smoking status, known; n (%)                                          1,853 (90.7%)
   Nonsmoker                                                            849 (45.8%)[a](#tfn5-jaa-8-001){ref-type="table-fn"}
   Current smoker                                                       322 (17.4%)[a](#tfn5-jaa-8-001){ref-type="table-fn"}
   Ex-smoker                                                            682 (36.8%)[a](#tfn5-jaa-8-001){ref-type="table-fn"}
  PEF (% predicted), n (%)                                              1,358 (66.5%)
   Mean (SD)                                                            69.3 (21.8)
  FEV~1~ (% predicted), n (%)                                           848 (41.5%)
   Mean (SD)                                                            59.0 (29.0)
  FEV~1~/FVC ratio, n (%)                                               780 (38.2%)
   Mean (SD)                                                            0.61 (0.24)
   ≥0.7, n (%)                                                          311 (39.9%)[a](#tfn5-jaa-8-001){ref-type="table-fn"}
  ICS prescribed, n (%)                                                 1,690 (82.8%)
  LABA prescribed, n (%)                                                1,385 (67.8%)
  Adherence to ICS (%), n (%)                                           1,690 (82.8%)
   Median (IQR)                                                         100 (73, 134)
  Controller-reliever ratio, n (%)                                      1,909 (93.5%)
   Median (IQR)                                                         0.50 (0.33, 0.71)
  Hospitalization, ≥1[b](#tfn6-jaa-8-001){ref-type="table-fn"}; n (%)   
   A&E                                                                  25 (1.2%)
   Inpatient                                                            22 (1.1%)
   Outpatient                                                           22 (1.1%)
  --------------------------------------------------------------------- ------------------------------------------------------

**Notes:** n=2,042, unless otherwise noted;

percentage of patients with data for that variable

at least one asthma-related hospital visit during baseline year (categorized).

**Abbreviations:** A&E, Accident and Emergency Department; BMI, body mass index; FEV~1~, forced expiratory volume in one second, expressed as percentage of predicted normal; FVC, forced vital capacity; ICS, inhaled corticosteroid; IQR, interquartile range; LABA, long-acting β~2~ agonist; PEF, peak expiratory flow, expressed as percentage of predicted normal; SD, standard deviation.

###### 

Comparison of effectiveness measures before (baseline) and after (outcome) addition of tiotropium

                                                                  Baseline         Outcome          *P*-value[a](#tfn9-jaa-8-001){ref-type="table-fn"}
  --------------------------------------------------------------- ---------------- ---------------- ----------------------------------------------------
  Exacerbations                                                                                     
   ≥1, n (%)                                                      752 (36.8%)      543 (26.6%)      \<0.001
  Acute respiratory events                                                                          
   ≥1, n (%)                                                      1,191 (58.3%)    965 (47.3%)      \<0.001
  Risk domain of asthma control                                                                     
   Controlled, n (%)                                              846 (41.4%)      1,071 (52.4%)    \<0.001[b](#tfn10-jaa-8-001){ref-type="table-fn"}
  Acute OCS courses                                                                                 
   ≥1, n (%)                                                      732 (35.8%)      521 (25.5%)      \<0.001
  Antibiotic prescriptions                                                                          
   ≥1, n (%)                                                      1,043 (51.1%)    842 (41.2%)      \<0.001
  PEF (% predicted), n (%)                                        926 (45.3%)      926 (45.3%)      
   Mean (SD)                                                      70.0 (21.5)      69.5 (21.7)      0.371[c](#tfn11-jaa-8-001){ref-type="table-fn"}
  FEV~1~ (% predicted), n (%)                                     398 (19.5%)      398 (19.5%)      
   Mean (SD)                                                      58.0 (29.5)      57.9 (30.5)      0.935[c](#tfn11-jaa-8-001){ref-type="table-fn"}
  FEV~1~/FVC ratio, n (%)                                         353 (17.3%)      353 (17.3%)      
   \<0.5, n (%)[d](#tfn12-jaa-8-001){ref-type="table-fn"}         91 (25.8%)       116 (32.9%)      0.382
   0.5--0.69, n (%)[d](#tfn12-jaa-8-001){ref-type="table-fn"}     122 (34.6%)      86 (24.4%)       
   ≥0.7, n (%)[d](#tfn12-jaa-8-001){ref-type="table-fn"}          140 (39.7%)      151 (42.8%)      
  SABA usage (μg/day)[e](#tfn13-jaa-8-001){ref-type="table-fn"}                                     
   Median (IQR)                                                   274 (110, 548)   329 (110, 603)   0.010[f](#tfn14-jaa-8-001){ref-type="table-fn"}

**Notes:** n=2,042 unless otherwise noted;

marginal homogeneity test, unless otherwise noted

McNemar test

paired t-test

percentage of 353 patients with paired FEV~1~/FVC ratio data

in salbutamol (albuterol) equivalents

Wilcoxon signed-rank test.

**Abbreviations:** FEV~1~, forced expiratory volume in one second, expressed as percentage of predicted normal; FVC, forced vital capacity; IQR, interquartile range; OCS, oral corticosteroid; PEF, peak expiratory flow, expressed as percentage of predicted normal; SABA, short-acting β~2~ agonist; SD, standard deviation.

###### 

Sensitivity analysis: baseline patient characteristics

  Variable                       Total                                                   Age ≤40 years                                           Age \>40 years
  ------------------------------ ------------------------------------------------------- ------------------------------------------------------- -------------------------------------------------------
  Age (years), n (%)             928 (100%)                                              136 (14.7%)                                             792 (85.3%)
   Mean (SD)                     61.3 (16.3)                                             33.6 (5.8)                                              66.1 (12.2)
  Gender, female; n (%)          601 (64.8%)                                             97 (16.1%)                                              504 (83.9%)
  Smoking status, known; n (%)   884 (95.3%)                                             123 (13.9%)[a](#tfn16-jaa-8-001){ref-type="table-fn"}   761 (86.1%)[a](#tfn16-jaa-8-001){ref-type="table-fn"}
   Nonsmoker                     674 (76.2%)[b](#tfn17-jaa-8-001){ref-type="table-fn"}   58 (8.6%)                                               616 (91.4%)
   Current smoker                79 (8.9%)[b](#tfn17-jaa-8-001){ref-type="table-fn"}     39 (49.4%)                                              40 (50.6%)
   Ex-smoker                     131 (14.8%)[b](#tfn17-jaa-8-001){ref-type="table-fn"}   26 (19.8%)                                              105 (80.2%)
  PEF (% predicted); n (%)       615 (66.3%)                                             89 (14.5%)                                              526 (85.5%)
   Mean (SD)                     72.8 (22.1)                                             67.4 (20.1)                                             73.7 (22.3)
  FEV~1~ (% predicted); n (%)    351 (37.8%)                                             43 (12.3%)                                              308 (87.7%)
   Mean (SD)                     74.9 (27.5)                                             59.6 (25.2)                                             77.0 (27.2)
  FEV~1~/FVC ratio, n (%)        328 (35.3%)                                             40 (12.2%)                                              288 (87.8%)
   Mean (SD)                     0.8 (0.2)                                               0.7 (0.3)                                               0.8 (0.2)

**Notes:**

Within-row percentages for the two age groups represent percentage of the total number of patients in that row

percentage of 884 patients whose smoking status was known.

**Abbreviations:** FEV~1~, forced expiratory volume in one second, expressed as percentage of predicted normal; FVC, forced vital capacity; PEF, peak expiratory flow, expressed as percentage of predicted normal; SD, standard deviation.

###### 

Sensitivity analysis: comparison of primary measures before (baseline) and after (outcome) addition of tiotropium

  Variable                   Baseline      Outcome       *P*-value[a](#tfn20-jaa-8-001){ref-type="table-fn"}
  -------------------------- ------------- ------------- -----------------------------------------------------
  Exacerbations                                          
   ≥1, n (%)                 363 (39.1%)   274 (29.5%)   \<0.001
  Acute respiratory events                               
   ≥1, n (%)                 567 (61.1%)   452 (48.7%)   \<0.001

**Notes:** n=928;

marginal homogeneity test.
